Previous 10 | Next 10 |
Whether you're a relatively new investor or have been putting your money to work for many decades, what you've witnessed over the past five weeks is unlike anything anyone has ever seen before. The spread of COVID-19 has pushed equities into bear market territory faster than any previous corr...
Stating the obvious, Baird analysts have created three lists of healthcare companies that may be worth a look considering their attractive valuations or relatively strong capitalizations amid the COVID-19 selloff. More news on: IDEAYA Biosciences, Inc., Surface Oncology, Inc., Jounce Thera...
Introduction It is remarkable how few articles have been published about Genfit ( GNFT) lately on Seeking Alpha. The last articles dated from June and August last year. This is quite remarkable since the company is nearing its make-or-break moment and indicates that investors’ ...
Intercept Pharmaceuticals ( ICPT +9.5% ) is up on below-average volume in response to a draft report from the non-profit Institute for Clinical and Economic Review (ICER) that is supposedly supportive of the cost-effectiveness of obeticholic acid (OCA) for the treatment of nonalcoholic s...
Business disruptions due to COVID-19 represent a new risk for investors across all sectors. Expect to see language addressing this added to the risk factors section of 10-K annual reports filed with the Securities and Exchange Commission (SEC). For biotech and pharma companies, COVID-19 will im...
Today, we will see why Intercept Pharmaceuticals (ICPT) can be an attractive albeit high-risk pick in 2020. Company overview Intercept Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies targeting progressive non-v...
NEW YORK, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski, M.D., President a...
Image source: The Motley Fool. Intercept Pharmaceuticals Inc (NASDAQ: ICPT) Q4 2019 Earnings Call Feb 25, 2020 , 8:30 a.m. ET Operator Continue reading
Intercept Pharmaceuticals, Inc. (ICPT) Q4 2019 Earnings Conference Call February 25, 2020 08:30 ET CompanyParticipants Lisa DeFrancesco - VP, IR Mark Pruzanski - CEO Jerry Durso - COO Sandip Kapadia - CFO Conference Call Participants Brian Abrahams - RBC Capital Markets ...
The following slide deck was published by Intercept Pharmaceuticals, Inc. in conjunction with their 2019 Q4 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...